Cross Border Exits for HealthTech, Health AI, MedTech, Digital Health Founders: Why Your Most Likely Buyer Isn't in Your Country

Nelson Advisors
11 hours ago
13 min read

Executive Summary

The European healthcare technology and medical device ecosystem has entered an era of disciplined maturity. The speculative valuation inflation of the early 2020s has given way to a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience and technological defensibility. Within this landscape, European founders face a structural reality: domestic exit options are frequently constrained by fragmented national healthcare systems, localized reimbursement schemes, and limited domestic growth capital.

Consequently, the premium buyer for a European HealthTech or MedTech asset is overwhelmingly cross-border, typically a US strategic acquirer, a pan-European consolidator, or a large German or Nordic corporate buyer.

While foreign acquirers command deeper balance sheets and offer significant valuation premiums—often 15% to 20% higher than domestic alternatives, cross-border transactions introduce deep operational and regulatory complexity. The acquisition process is no longer a straightforward negotiation of enterprise value; it is an intricate exercise in regulatory clearance and operational standardization.

Foreign Direct Investment (FDI) screening regimes, such as the United Kingdom's National Security and Investment Act (NSI Act) and the European Union's revised FDI Screening Regulation (Regulation (EU) 2026/1386), routinely extend transaction timelines to between 12 and 30 weeks. Simultaneously, evolving health data sovereignty mandates, exemplified by the European Health Data Space (EHDS) Regulation—require targets to maintain localised compliance while presenting an architecture that can be integrated globally.

To capture top-tier cross-border valuations, European health founders must make their organizations internationally legible long before entering an M&A process.

This report provides an analysis of cross-border exit dynamics, dissecting buyer motivation, regulatory screening mechanisms, data governance mandates, and accounting and operational alignment strategies.

The Economics of Cross-Border Premiums and Buyer Typologies

Valuation Divergence and Strategic Rationale

Cross-border buyers in the HealthTech and MedTech sectors display a higher willingness to pay than domestic peers due to structural synergies, market entry imperatives, and broader capital deployment capabilities. US strategic buyers, operating within the world's largest unified healthcare market, seek European assets to obtain validated technologies that can be scaled across their existing domestic distribution networks. Pan-European buy-and-build platforms, backed by private equity sponsors holding substantial dry powder, acquire regional category leaders to consolidate fragmented healthcare IT verticals. German and Nordic corporate buyers target specialised digital health solutions to modernise domestic health systems and fulfil digital infrastructure mandates.

In the current M&A environment, market valuations exhibit a severe bifurcation between high-performing assets and secondary targets. Companies demonstrating strong unit economics, high net retention and compliance with the "Rule of 40" (where the sum of revenue growth rate and free cash flow margin equals or exceeds 40%) command premium multiples. Conversely, early-stage or unprofitable assets with high burn rates experience significant valuation compression.

Sub-Sector Vertical	Enterprise Value / Revenue Multiple	Enterprise Value / EBITDA Multiple	Key Strategic Valuation Drivers
Premium AI & Data Platforms	6.0x – 8.0x+	15.0x – 18.0x+	Proprietary algorithms, clean/validated datasets, Rule of 40 performance, clinical interpretability.
Value-Based Care (VBC)	5.5x – 7.0x	12.0x – 15.0x	Demonstrable ROI for payers, population health management tools, risk-sharing infrastructure.
AI-First Drug Discovery	8.0x – 15.0x	N/A	High-risk/high-reward biopharma capability multipliers, defensible IP portfolios.
Hybrid Telehealth Platforms	5.0x – 7.0x	11.0x – 14.0x	Integrated virtual and in-person delivery networks, long-term provider contracts.
Standard HealthTech SaaS	4.0x – 6.0x	10.0x – 14.0x	High net retention (>110%), EBITDA margins >20%, predictable recurring revenue.
MedTech Hardware (MDR-Ready)	3.5x – 5.5x	11.0x – 14.0x	Certified regulatory moats, established supply chain resilience, high barriers to entry.
Consumer Health & Wellness	2.0x – 4.0x	8.0x – 11.0x	Vulnerable to discretionary spending shifts, higher subscriber churn.
Unprofitable / Early-Stage	3.0x – 4.0x	N/A	High cash burn, candidates for distressed M&A or asset roll-ups.

Compliance-Driven M&A and Regulatory Arbitrage

A major catalyst behind the premium prices paid by US strategic acquirers is "compliance driven M&A". European regulatory approvals, specifically under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have created an operational bottleneck. The acute scarcity of designated Notified Bodies in Europe has resulted in an 18-to-24-month regulatory timeline for non-certified devices entering the market.

US strategic buyers frequently use M&A to acquire European target entities that have already secured MDR certification. By acquiring an MDR-certified target, a foreign buyer bypasses the multi-year regulatory backlog, gaining immediate access to the European market while simultaneously leveraging its own capital infrastructure to commercialize the asset in the US under FDA pathways. This regulatory shortcut generates an immediate top-line expansion for the acquirer, justifying a 15% to 20% valuation premium over non-certified equivalents.

Concurrently, the enforcement of the EU Artificial Intelligence Act imposes strict requirements on clinical AI systems. The regulation mandates "glass box" model interpretability, robust data governance and continuous bias auditing for high-risk healthcare applications. Acquirers apply steep valuation discounts often exceeding 30%, to targets utilising "black box" algorithms or wrapper interfaces over third-party APIs. Conversely, targets possessing proprietary, explainable algorithms trained on clean, clinically validated datasets capture peak market multiples.

Navigating Foreign Direct Investment (FDI) and National Security Screening

The UK National Security and Investment Act (NSI Act)

Cross-border transactions involving UK-based health technology entities are subject to statutory scrutiny under the UK National Security and Investment Act 2021 (NSI Act). The NSI Act grants the UK government broad powers to review, condition, or block acquisitions that potentially compromise national security. Mandatory notification is triggered when an acquirer's shareholding or voting rights cross specific statutory thresholds: moving from 25% or less to more than 25%, from 50% or less to more than 50%, or reaching 75% or more.

In the life sciences and healthcare domains, mandatory notifications are frequently triggered under three key sectors specified in the Notifiable Acquisition Regulations:

Synthetic Biology: Broadly defined to cover the design and engineering of biological-based parts of enzymes, genetic circuits, cells, novel systems, and gene editing technologies. While routine industrial biotechnology using unmodified enzymes and certain human/veterinary immuno-modulatory therapies are granted exemptions, targets involved in advanced gene delivery systems or synthetic platforms remain strictly reportable.
Artificial Intelligence: Revisions to the regime clarify that mandatory reporting applies to entities researching or developing AI specifically used for advanced robotics, cybersecurity, or identifying and tracking individuals. Non-consumer AI used for routine business operations or third-party licensed AI integrations are generally excluded to prevent over-reporting.
Data Infrastructure and Emergency Services: Targets operating health data processing hubs, public safety infrastructure, or specialised cloud storage supporting emergency services fall within mandatory screening thresholds.

Procedurally, the NSI Act screening process follows a structured timeline that directly impacts deal closing certainty:

Mandatory Notification Filing: The acquirer submits a formal notification to the Investment Security Unit (ISU) detailing corporate ownership structures, target operations, and technical IP capabilities.
Initial Review Period: Once the notification is formally accepted as complete, the ISU has a statutory period of 30 working days (approximately 6 calendar weeks) to review the transaction and either grant clearance or issue a call-in notice.
Detailed Assessment Phase: If the acquisition is called in for a full national security assessment, an additional 30-working-day review period is initiated. The Secretary of State can extend this period by a further 45 working days if national security risks are identified.
Information Requests and Clock-Pauses: The issuance of formal Information Notices or Attendance Notices pauses the statutory review clock until the parties satisfy the query, frequently adding 4 to 12 weeks to the review schedule.
Final Determination: The transaction is either cleared unconditionally, granted conditional clearance subject to behavioural or structural remedies (such as data ring-fencing or local board requirements), or prohibited.

Consequently, transactions subject to NSI Act review routinely require 12 to 30 weeks between deal signing and closing. Attempting to complete a mandatory notifiable transaction without prior clearance renders the acquisition legally void and exposes corporate officers to severe civil and criminal penalties.

The Harmonised EU FDI Regime and German AWV Regulations

Across continental Europe, foreign investment screening has shifted from an uncoordinated patchwork to a harmonized, security-centric regulatory framework. The adoption of Regulation (EU) 2026/1386 (repealing and replacing Regulation (EU) 2019/452) establishes a mandatory baseline for foreign investment screening across all 27 EU Member States.

The revised EU FDI framework introduces several provisions that impact cross-border M&A strategy:

Scope and the "Xella Gap": The regulation explicitly closes the historical legal loophole identified in the CJEU Xella judgment. Screening mechanisms now extend to indirect intra-EU acquisitions, capturing scenarios where a non-EU investor acquires control over an EU target through an EU-based intermediate holding company or subsidiary.
Mandatory Sectoral Floor: All Member States must enforce prior authorization regimes for foreign acquisitions targeting critical capabilities. Key sectors include AI systems carrying systemic risks, advanced semiconductors, quantum technologies, biotechs, critical raw materials, and health-adjacent data infrastructures.
Review Timelines: The regulation introduces a capped initial review period of 45 calendar days. However, multi-jurisdictional transactions trigger the EU cooperation mechanism, requiring parties to file simultaneous notifications across all affected Member States, which can expand total clearance windows to 24–30 weeks.
Post-Closing Retroactive Call-In Powers: National authorities must maintain statutory powers to retroactively call in completed transactions that were not subject to mandatory prior notification. The call-in period spans at least 15 months and up to five years post-closing for unnotified transactions raising security concerns, and at least two years post-closing for non-compliant mandatory filings.

At the Member State level, Germany exemplifies rigorous foreign direct investment screening under its Foreign Trade and Payments Ordinance (Außenwirtschaftsverordnung – AWV) managed by the Federal Ministry for Economic Affairs and Climate Action (BMWK). For targets operating in critical healthcare sectors, including medical software, diagnostic infrastructures, health telematics, and critical pharmaceuticals, the AWV enforces a low 10% voting share threshold for mandatory cross-sectoral screening. German FDI reviews frequently evaluate key-person retention, data sovereign hosting and technology transfer restrictions, making early engagement with the BMWK essential for cross-border buyers.

Regulatory Regime	Statutory Scope & Thresholds	Initial Review Window	Full Assessment Window	Retroactive Call-In Period	Key Healthcare & Tech Focus Areas
UK NSI Act	Mandatory for 17 sensitive sectors; voting/share thresholds >25%, >50%, ≥75%.	30 working days (~6 calendar weeks).	+30 to +45 working days (clock stops on info requests).	5-year retroactive call-in window for non-notified transactions.	Synthetic biology, clinical AI, emergency health services, data hubs.
EU FDI Regulation (EU 2026/1386)	Mandatory minimum scope across all 27 Member States; captures indirect EU holdings.	Capped at 45 calendar days.	Multi-state EU cooperation adds 6 to 12 weeks.	15 months up to 5 years for completed non-notified deals.	Systemic AI, biotechnology, health data networks, critical supply chains.
German AWV (BMWK)	Cross-sectoral mandatory reporting for critical health assets; voting threshold ≥10%.	2 months (Phase I preliminary review).	4 to 8 months (Phase II national security review).	Up to 5 years post-closing for unnotified acquisitions.	Critical health IT, hospital software, diagnostic infrastructure, telematics.

Health Data Sovereignty: Structural Moat vs. Deal Complication

The European Health Data Space (EHDS) Framework

Health data governance in Europe has transitioned from basic regulatory compliance under GDPR to a structural operational requirement under Regulation (EU) 2025/327, establishing the European Health Data Space (EHDS). The EHDS framework bifurcates health data usage into two distinct operational paradigms:

Primary Use (MyHealth@EU): Governs the secure cross-border exchange of personal electronic health data (e.g., electronic health records, patient summaries, digital prescriptions) to deliver direct medical care across EU Member States.
Secondary Use (HealthData@EU): Establishes a mandatory framework allowing researchers, commercial entities, and technology developers to access de-identified health data for scientific research, innovation, algorithm training, and regulatory activities.

In practice, a target healthtech platform manages primary data through localised European Health Record (EHR) systems that incorporate patient opt-out controls and adhere to EU interoperability formats. The secondary data layer processes research datasets through national Health Data Access Bodies (HDABs), ensuring all data is fully anonymized or pseudonymized before use.

When a non-EU acquirer buys the company, integration occurs at an external gateway layer. Rather than pulling raw patient records out of the EU, the acquirer interfaces with the platform through localized API abstraction layers and secure statutory permits, preserving data sovereignty while acquiring computational and commercial utility.

For foreign acquirers—particularly US corporates accustomed to proprietary data consolidation—the secondary use mandates present both opportunities and structural risks. Under the EHDS, health data holders (including private healthtech firms) are required to make health datasets available to national HDABs for approved secondary research and AI development. While this grants acquirers unprecedented access to broad European datasets, it simultaneously restricts exclusive data monopolies. Data protected by intellectual property or trade secrets must still be disclosed for secondary processing, though HDABs are legally obligated to enforce protective measures, such as secure processing environments and technical access restrictions.

Cross-Border Data Transfer and Cloud Architecture

A major deal-breaker during transatlantic due diligence is the non-compliant transfer of European personal health data to foreign jurisdictions. US acquirers often assume that acquiring an entity grants them full rights to pull target data into US-based centralised data lakes. Under GDPR and EHDS mandates, direct export of raw European health records to non-adequate third countries without robust transfer mechanisms (e.g., Standard Contractual Clauses combined with supplementary technical safeguards) is legally non-viable.

To resolve this friction without devaluing the deal, European founders must architect their data infrastructure around localised tenancy and technical abstraction prior to sale:

Tenant Isolation and Localized Cloud Hosting: HealthTech software platforms must utilize localized EU hosting facilities (e.g., AWS Frankfurt, Azure Dublin, or sovereign European cloud providers). Database architectures should implement strict logical and geographic tenant isolation, ensuring personal health data remains strictly within EU boundaries.
API Abstraction Layers: Systems should be engineered with localized API gateways. The foreign acquirer's global enterprise platform interacts with the target system exclusively through secure, authenticated APIs that expose anonymised outputs or synthetic data models, keeping raw identifiable patient data localised within the EU infrastructure.
Algorithmic Model Export vs. Data Export: When selling an AI-driven target, the financial value resides in the trained algorithmic parameters, not the underlying raw patient records. Founders must structure their machine learning pipelines so that model training occurs locally within the EU environment. The resulting trained model weights (non-personal mathematical abstractions) can then be lawfully transferred cross-border to the foreign parent company.

Operational and Financial Legibility: Preparing the Asset for Acquirers

Financial and Revenue Alignment

A common obstacle during cross-border M&A diligence is the divergence between local European accounting practices and foreign corporate accounting standards, specifically US GAAP. European HealthTech companies frequently report financial performance using local GAAP or simplified IFRS formats that obscure unit economics when reviewed by a US strategic buyer.

To ensure financial legibility, targets must align their revenue recognition and capitalisation practices with international standards well ahead of an exit process:

Revenue Recognition (IFRS 15 / ASC 606): HealthTech platforms operating multi-year enterprise contracts with hospitals or public health authorities often bundle software licenses, hardware delivery, custom implementation, and ongoing maintenance. Under IFRS 15 and ASC 606, companies must explicitly unbundle performance obligations and recognize revenue only when control of distinct goods or services transfers to the customer. Upfront implementation fees cannot be recognized immediately if they do not represent a standalone performance obligation.
R&D Capitalisation Policy: Under IFRS (IAS 38), development costs meeting strict technical feasibility criteria must be capitalised on the balance sheet, whereas US GAAP (ASC 350-40 / ASC 985-20) requires immediate expensing of most software research and development costs until technological feasibility is established. US buyers will reclassify capitalised R&D back into operating expenses, artificially lowering the target's historical EBITDA and impacting valuation calculations.
Reimbursement Model Translation: European health targets often derive revenues from localized statutory schemes, such as Germany's DiGA (Digitale Gesundheitsanwendungen), France's PECAN, or specific NHS specialized commissioning frameworks. Foreign acquirers struggle to model the persistence of these regional revenue streams. Founders must translate localised reimbursement traction into internationally recognisable metrics, such as Annual Recurring Revenue (ARR), Net Revenue Retention (NRR), Customer Acquisition Cost (CAC) payback periods, and ARR per Full-Time Employee (FTE).

Mitigating Key-Person Risk and Contracting Standardisation

Foreign buyers view key-person risk, the operational dependency on founder-clinicians or lead software architects, as a single point of failure. In European HealthTech, founders often hold primary relationships with local clinical key opinion leaders and regional regulatory authorities. If a founder exits immediately post-close, the value of the acquired asset can rapidly degrade.

To de-risk the transaction, cross-border consideration structures are typically divided across three core components:

Upfront Cash at Closing: Comprising 60% to 70% of total deal value, providing immediate liquidity to selling shareholders upon completion.
Rollover Equity: Accounting for 10% to 20% of consideration, key founders and executive team members roll over a portion of their proceeds into equity of the acquiring parent entity or holding platform, establishing long-term financial alignment.
Deferred Earnout Pools: Representing 10% to 20% of total value, structured as conditional earn outs tied to clear technical, regulatory, or financial milestones, such as achieving FDA clearance, reaching specific ARR targets, or transitioning hosting infrastructure.

Simultaneously, executives are required to sign employment agreements containing multi-year non-compete clauses, non-solicitation covenants and 24-to-36-month service requirements to earn out deferred compensation pools.

Operational legibility also requires standardising legal governance across all corporate assets. All core intellectual property assignment agreements with employees, contractors, and academic research partners must be clean, fully executed and governed under clear corporate ownership clauses. Master Services Agreements (MSAs) and commercial contracts should be executed in English, eliminating linguistic ambiguities and facilitating seamless legal due diligence by international counsel.

Strategic Blueprint for European Health Founders

Cross-border M&A offers European health founders access to top-tier strategic valuations and global market reach. However, navigating the structural friction between domestic innovation and international capital demands rigorous advance preparation.

Foreign Direct Investment regimes (UK NSI Act, EU FDI Regulation, German AWV) have converted deal execution into a protracted regulatory clearance process lasting up to 30 weeks. Concurrently, evolving data sovereignty frameworks require targets to balance compliance with international scalability.

To execute a successful cross-border exit, European founders should pursue a structured 12-to-24-month pre-process playbook:

Conduct an Early FDI Audit: Map supply chains, software dependencies, and investor cap tables against trigger thresholds under the UK NSI Act, EU FDI Regulation, and national screening regimes such as the German AWV. Engage regulatory counsel early to draft notification strategies and incorporate long-stop clearance buffers into transaction timetables.
Architect for Data Sovereignty: Decouple core clinical datasets from algorithmic outputs. Implement localised EU cloud hosting, enforce strict tenant isolation, and build localized API gateways so that international acquirers can extract algorithmic value without violating GDPR or EHDS cross-border transfer restrictions.
Institutionalize Financial and Contractual Reporting: Align accounting practices with IFRS 15 and ASC 606 standards, unbundle implementation fees from recurring software licenses, and resolve R&D capitalization discrepancies. Standardise all commercial contracts, vendor agreements, and IP assignments in English.
De-Risk Key-Person and Regulatory Bottlenecks: Secure MDR and IVDR certifications early to leverage the 18-to-24-month Notified Body shortage as a high-value asset for foreign buyers seeking immediate European market entry. Institutionalise clinical operational knowledge across broader management tiers to eliminate single-point founder dependency, preparing the executive team for equity rollover and structured retention programs.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics